EANM/SNMMI 2019 嗜铬细胞瘤与副神经节瘤核素显像实践指南
该指南由 EANM 与 SNMMI 联合发布,面向核医学从业者,规范嗜铬细胞瘤和副神经节瘤(PPGL)的 SPECT 与 PET 显像选择、操作、结果判读与报告。指南指出 68Ga 标记生长抑素类似物显像简化了 PPGL 影像路径,并可用于筛选肽受体核素治疗患者;基因组特征正在细化遗传性 PPGL 的分子影像应用。
要点
- 68Ga 标记生长抑素类似物显像简化了 PPGL 影像路径,并可用于筛选肽受体核素治疗。
- 该显像可作为 123I/131I-MIBG 传统诊疗一体化方法的替代或补充。
- 基因组特征有助于细化遗传性 PPGL 的检测、分期与随访监测。
核心结论
- 68Ga 标记生长抑素类似物显像的优异结果简化了 PPGL 患者的影像路径,并可用于筛选肽受体核素治疗患者。
- 基因组特征正在细化分子影像在遗传性 PPGL 个性化检测、分期和随访监测中的应用。
研究设计与样本
- 该指南由 EANM 与 SNMMI 联合批准,参考相关领域指南和文献并与 PPGL 管理专家协商制定。
- 指南信息需根据当地法律法规及各种放射性药物的可获得性应用。
主要发现
- 68Ga 标记生长抑素类似物显像可作为肽受体核素治疗的患者筛选工具,作为 123I/131I-MIBG 传统诊疗一体化方法的潜在替代或补充。
- 基因组特征可区分不同病灶发展和转移风险的亚组,从而细化分子影像在遗传性 PPGL 个性化管理中的应用。
临床怎么用
- 核医学从业者应按指南选择和执行 SPECT 与 PET 显像程序,并规范结果判读与报告。
- 对 PPGL 患者可考虑 68Ga 标记生长抑素类似物显像以简化影像路径并筛选肽受体核素治疗候选人。
- 遗传性 PPGL 患者可结合基因组特征利用分子影像进行检测、分期和随访监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Diverse radionuclide imaging techniques are available for the diagnosis, staging, and follow-up of phaeochromocytoma and paraganglioma (PPGL). Beyond their ability to detect and localise the disease, these imaging approaches variably characterise these tumours at the cellular and molecular levels and can guide therapy. Here we present updated guidelines jointly approved by the EANM and SNMMI for assisting nuclear medicine practitioners in not only the selection and performance of currently available single-photon emission computed tomography and positron emission tomography procedures, but also the interpretation and reporting of the results. METHODS: Guidelines from related fields and relevant literature have been considered in consultation with leading experts involved in the management of PPGL. The provided information should be applied according to local laws and regulations as well as the availability of various radiopharmaceuticals. CONCLUSION: Since the European Association of Nuclear Medicine 2012 guidelines, the excellent results obtained with gallium-68 (68Ga)-labelled somatostatin analogues (SSAs) in recent years have simplified the imaging approach for PPGL patients that can also be used for selecting patients for peptide receptor radionuclide therapy as a potential alternative or complement to the traditional theranostic approach with iodine-123 (123I)/iodine-131 (131I)-labelled meta-iodobenzylguanidine. Genomic characterisation of subgroups with differing risk of lesion development and subsequent metastatic spread is refining the use of molecular imaging in the personalised approach to hereditary PPGL patients for detection, staging, and follow-up surveillance.
引用
- Taïeb D, Hicks RJ, Hindié E, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019. PMID: 31254038. doi:10.1007/s00259-019-04398-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。